The experience of weight gain during and after breast cancer treatment: a qualitative study
Breast Cancer Research and Treatment · 2025
DOI: 10.1007/s10549-024-07528-y ↗Kurz gefasst
Qualitative Studie in der Zeitschrift Breast Cancer Research and Treatment, 2025. Verfasst von Carolyn Ee und 8 weiteren Autor:innen. Beteiligte Einrichtung: NICM Health Research Institute, Western Sydney University, Locked Bag 1797, Penrith, NSW, 2751, Australia. c.ee@westernsydney.edu.au. Hauptthemen laut MEDLINE: Breast Neoplasms, Weight Gain. Die Arbeit nennt 23 Literaturangaben. Gefördert von: Primary Care Collaborative Cancer Clinical Trials group.
Abstract (Originalsprache)
PURPOSE: After breast cancer diagnosis and treatment, the majority of women will gain weight. The aim of this study was to describe the experiences of weight management among Australian women with breast cancer. METHODS: This is a secondary analysis of data from a qualitative study evaluating the feasibility of novel interventions for weight management after breast cancer. Participants were recruited via email invitation from a breast cancer consumer organization and breast cancer centre in Australia. Eligible participants had received treatment for breast cancer, and were fluent in English. Discussions were audio-recorded, transcribed verbatim and analysed using thematic analysis with the constant comparison method. RESULTS: Thirty-seven women provided data in five focus groups and one semi-structured interview. Four themes were identified: Timing, milestones and turning points; Making sense of the journey; Factors leading to weight gain; and Information and health professional support. Varying trajectories of weight gain were described, the most common being gradual or fluctuating weight gain. Weight gain was attributed to a number of related factors including becoming postmenopausal, and the impact of treatment effects. Achieving a sense of autonomy and agency assisted with weight management. An overall lack of information and support relating to weight management was highlighted. CONCLUSIONS: There is a need for a coordinated and systematic approach to weight management after breast cancer. Further research on the role of supportive care and systems-level support is warranted to mitigate the significant public health burden of excess weight after breast cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- NICM Health Research Institute, Western Sydney University, Locked Bag 1797, Penrith, NSW, 2751, Australia. c.ee@westernsydney.edu.au.
- Caring Futures Institute, Flinders University, Adelaide, SA, Australia. c.ee@westernsydney.edu.au.
- Translational Health Research Institute, Western Sydney University, Sydney, NSW, Australia. c.ee@westernsydney.edu.au.
- Engagement and Co-Design Research Hub, School of Health Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
- Daffodil Centre, University of Sydney, Sydney, NSW, Australia.
- Westmead Breast Cancer Institute, Sydney, NSW, Australia.
Förderung
- Primary Care Collaborative Cancer Clinical Trials group
Zitieren
APA
Ee, C., Singleton, A., Elder, E., Davis, N., Mitchell, C., Dune, T., MacMillan, F., McBride, K., & Grant, S. (2025). The experience of weight gain during and after breast cancer treatment: a qualitative study. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07528-y
Vancouver
Ee C, Singleton A, Elder E, Davis N, Mitchell C, Dune T, et al. The experience of weight gain during and after breast cancer treatment: a qualitative study. Breast Cancer Research and Treatment. 2025. doi:10.1007/s10549-024-07528-y
BibTeX
@article{Ee2025,
author = {Ee, Carolyn and Singleton, Anna and Elder, Elisabeth and Davis, Nikki and Mitchell, Christine and Dune, Tinashe and MacMillan, Freya and McBride, Kate and Grant, Suzanne},
title = {The experience of weight gain during and after breast cancer treatment: a qualitative study},
journal = {Breast Cancer Research and Treatment},
year = {2025},
doi = {10.1007/s10549-024-07528-y}
}
EUVIMED